Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402

Table 1 Clinical profiles of enrolled patients

Patients	Age	Sex	Primary sites	Sites of metastases	Stage	PS	Previous Tx
P1	41	female	Skin (back)	Liver, Spleen, Skin	IV	0	S/C
P2	74	female	Skin (knee)	Lymph nodes	IV	0	S/C
P3	58	male	Ocular	Liver, Stomach	IV	0	S/C
P4	69	male	Skin (chest)	Lung, Liver	IV	1	S/C
P5	35	male	Ocular	Liver	IV	0	R/C
P6	52	male	Nasal cavity	Lymph node, Skin	IV	0	R

The six HLA-A*2402-positive patients with stage IV melanoma initially enrolled in this clinical trial are shown in this table. All patients had relatively good performance status (PS) and had previously undergone treatments (Tx), for example surgery (S), chemotherapy (C), and radiation therapy (R).

ISSN: 1479-5876